|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 16, 2017 ) Flu is an upper respiratory tract malady and is caused by the flu infection. Flu infection is fundamentally three sorts to be specific Influenza An, Influenza B, and Influenza C. Flu is a transferable malady, spread through this season's flu virus hack, beads from the tainted individuals, sniffle or talks. The regular indications happen in flu patients are chills, hack, running nose, sore throat, body throbs, cerebral pain, weariness, a few cases individuals may have retching and looseness of the bowels. The intricacy of the sickness may incorporate ear diseases, bacterial pneumonia, lack of hydration, sinus contaminations, and infrequently it prompts congestive heart disappointment, and asthma. Flu ordinarily happens in geriatric populace and kids with under 5 years old. The disease might be affirmed by testing the sputum, nose, or throat for the infection. Various fast tests are accessible however polymerase chain response that identifies the infection's RNA is more precise.
The U.S. Influenza market is growing at a significant CAGR due to rise in new born babies, and increase in geriatric population. Increase in vaccination awareness, favourable reimbursement scenario, and rising investment by companies in research and development activities are the major factors fuelling the growth of U.S. influenza market over the forecast period. The major market players have great pipeline products, initiatives by government bodies such as WHO and CDC to control and prevent influenza, technological advancements in diagnostic tests also fuel the growth of U.S. influenza market over the forecast period. However, limited production capacity, a high level of required investment, and stringent regulatory policies for new product approvals might hamper the growth of U.S. Influenza market. Due to limitations in current technologies, the lengthy production times (approximately seven months), increase in prices of influenza diagnostic kits and reagents also hinder the U.S. Influenza market.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/u-s-influenza-market/#ulp-4H8Z4LpNMLEuOnnx
The U.S. Influenza market is segmented on the basis of product type, distribution channel, and end user
Based on drug class, U.S. influenza market is segmented into the following:
• Anti-viral drugs
• Zanamivir
• Oseltamivir
• Amantadine
• Rimantadine
• Others
• Interferons
• Vaccines
• Trivalent
• Quadrivalent
Based on the route of administration, U.S. influenza market is segmented into the following:
• Oral
• Parenteral
• Others
Based on distribution channel U.S. influenza market is segmented into the following:
• Hospital pharmacies
• Retail pharmacies
• Others
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/u-s-influenza-market/#ulp-c654SbFYO64MsOhu
Influenza vaccines are key revenue contributor for the growth of U.S. influenza market. The U.S. influenza market is in growing phase, several international players are actively involved in the development of vaccines and drugs to treat influenza. Launch of new products, technological innovations, and approvals from U.S. Food and Drug Administration (FDA) for various drugs might fuel the growth of U.S. influenza market. For instance, Sequires used both egg and cell-based technologies to offer the broadcast portfolio of influenza vaccines in the U.S. for both trivalent and quadrivalent formulations. Similarly, transformative changes in other Vaccine markets, due to the entrance of expensive and innovative vaccines such as Gardasil (Merck) and Bexsero (GSK) are projected to contribute growth of the U.S. influenza market.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/u-s-influenza-market/#ulp-14mlyhjMGhVjZqa3
U.S. holds a dominant share in the global influenza market. The largest share is attributed to the higher rate of in-vitro diagnostics availability and technological advancements in medical devices which are primarily driving the U.S. Influenza market growth. As per CDC, persons above 6 months of age could be vaccinated to prevent the influenza infection. Increase in prevalence and incidence cases of influenza (According to CDC, about 5 to 20 percent of the U.S. people are infected with influenza in every year. CDC also states that about 200,000 people hospitalized and more than 36,000 people are dying from influenza in U.S) might increase the growth of U.S. influenza market. Similarly, upsurge in funding by the government is also driving the market growth in the United States. The U.S. government awarded 5-year contracts for more than US$ 1 Bn to five drug manufacturers developing technology for speedier mass production of influenza vaccines
Some of the players in U.S. influenza market are AstraZeneca (U.K.), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sanofi (France), Seqirus (U.K.), Protein Sciences Corporation (U.S.), Emergent Biosolutions (U.S.), BioCryst Pharmaceuticals.Inc (U.S.)., Alvogen (South Korea), Medimmune Inc. (U.S.), DynPort Vaccine Company, LLC. (U.S.), and Abbott Laboratories (U.S.) to name a few.
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
Precision Business Insights
Sales
+1-866-598-1553
sales@precisionbusinessinsights.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
